Health Ever Bio-Tech Co., Ltd.

23F-5, No. 95, Sec. 1, Xintai 5th Rd., New Taipei City, New Taipei, Taiwan

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

50.0%

Phase 2

37.5%

Phase 1

12.5%

Trial Status Distribution

Active, not recruiting

12.5%

Completed

50.0%

Terminated

25.0%

Unknown

12.5%

Clinical Trials

Trials sponsored by this organization (8)

To Evaluate the Effect of MCS® in Prostate Cancer Prevention

Phase 2

Active, not recruiting

interventional

Oct 2014702 participants

Pharmacokinetics of MCS in Healthy Volunteers

Phase 1

Unknown

interventional

Aug 201112 participants

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Phase 3

Completed

interventional

Jan 2011200 participants

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Phase 3

Completed

interventional

Aug 2010180 participants

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Phase 3

Terminated

interventional

Jul 200785 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations

Health Ever Bio-Tech Co., Ltd.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (8)

To Evaluate the Effect of MCS® in Prostate Cancer Prevention

Pharmacokinetics of MCS in Healthy Volunteers

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

MCS in the Treatment of Lower Urinary Tract Symptoms

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Approvals

News